tbuckley/cabot-search huggingface dataset:
Capillary Blood Flow Abnormalities in the Skeletal Muscle and Microvascular Complications in Diabetes: Lessons That Cannot Be Learned From Larger Vessels⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Thomas R. Porter
Journal: Journal of the American College of Cardiology (2009)
Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing
Authors: Irina Arnaoutova, Lisa Zhang, Hung-Dar Chen, Brian C. Mansfield, Janice Y. Chou
Journal: Molecular Therapy (2020)

Glycogen storage disease type Ia (GSD-Ia), deficient in glucose-6-phosphatase-α (G6PC), is characterized by impaired glucose homeostasis and a hallmark of fasting hypoglycemia. We have developed a recombinant adeno-associated virus (rAAV) vector-mediated gene therapy for GSD-Ia that is currently in a phase I/II clinical trial. While therapeutic expression of the episomal rAAV-G6PC clinical vector is stable in mice, the long-term durability of expression in humans is currently being established. Here we evaluated CRISPR/Cas9-based in vivo genome editing technology to correct a prevalent pathogenic human variant, G6PC-p.R83C. We have generated a homozygous G6pc-R83C mouse strain and shown that the G6pc-R83C mice manifest impaired glucose homeostasis and frequent hypoglycemic seizures, mimicking the pathophysiology of GSD-Ia patients. We then used a CRISPR/Cas9-based gene editing system to treat newborn G6pc-R83C mice and showed that the treated mice grew normally to age 16 weeks without hypoglycemia seizures. The treated G6pc-R83C mice, expressing ≥ 3% of normal hepatic G6Pase-α activity, maintained glucose homeostasis, displayed normalized blood metabolites, and could sustain 24 h of fasting. Taken together, we have developed a second-generation therapy in which in vivo correction of a pathogenic G6PC-p.R83C variant in its native genetic locus could lead to potentially permanent, durable, long-term correction of the GSD-Ia phenotype.
High-Density Lipoprotein Particle Number: A Better Measure to Quantify High-Density Lipoprotein?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Emil M. deGoma, Daniel J. Rader
Journal: Journal of the American College of Cardiology (2012)
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
Authors: Suchita Pakkala, Kristin Higgins, Zhengjia Chen, Gabriel Sica, Conor Steuer, Chao Zhang, Guojing Zhang, Shuhua Wang, Mohammad S Hossain, Bassel Nazha, Tyler Beardslee, Fadlo R Khuri, Walter Curran, Sagar Lonial, Edmund K Waller, Suresh Ramalingam, Taofeek K Owonikoko
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as salvage therapy in relapsed small cell lung cancer (SCLC). We conducted this signal-finding study to assess the efficacy of ICB with or without radiation in relapsed SCLC. Methods Patients with relapsed SCLC and ≤2 previous lines of therapy were randomized to (1) arm A: durvalumab (D) 1500 mg/tremelimumab (T) 75 mg (intravenously every 4 weeks without stereotactic body radiation therapy (SBRT)) or (2) arm B: immune-sensitizing SBRT to one selected tumor site (9 Gy × 3 fractions) followed by D/T. Treatment continued until progression or a maximum of 12 months. The co-primary endpoints of the study were overall response rate (ORR) and progression-free survival (PFS). We evaluated circulating lymphocyte repertoire in serial peripheral blood samples and tumor infiltrating lymphocytes (TILs) from on-treatment biopsies as pharmacodynamic markers. Results Eighteen patients were randomized to arms A and B (n=9 each): median age 70 years; 41.2% women. The median PFS and ORR were 2.1 months and 0% in arm A and 3.3 months and 28.6% in arm B. The median overall survival (OS) was 2.8 months in arm A and 5.7 months in arm B (p=0.3772). Pooled efficacy of D/T±SBRT in 15 Response evaluation criteria in solid tumors (RECIST) evaluable patients across both arms showed the best ORR in terms of partial response in 13.3%, stable disease in 26.6% and progressive disease in 60.0%; the overall median PFS and OS were 2.76 and 3.9 months. The most common adverse events were grade 1 fatigue (66%) and grade 1 elevated amylase (56%) in arm A, and grade 1 fatigue (56%) and pain (44%) in arm B. There was a significant increase in activated CD8(+)ICOS+ T cells (p=0.048) and a reduction in naïve T cells (p=0.0454) in peripheral blood following treatment, along with a significant amount of activated CD8+ICOS+ T cells in TILs from responders. Conclusions The D/T combination with and without SBRT was safe but did not show sufficient efficacy signal in relapsed SCLC. Changes in peripheral blood lymphocyte and TILs were consistent with an immunologic response. Trial registration number NCT02701400 .
Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease
Authors: Alexander P Benz, Jeff S Healey, Ashley Chin, Patrick Commerford, Tamara Marsden, Ganesan Karthikeyan, William F McIntyre, Jorge A Wong, Albertino Damasceno, Stefan H Hohnloser, Jonas Oldgren, Lars Wallentin, Michael D Ezekowitz, John W Eikelboom, Salim Yusuf, Stuart J Connolly
Journal: Cardiovascular Research (2020)

Patients with atrial fibrillation (AF) and rheumatic heart disease (RHD), especially mitral stenosis, are assumed to be at high risk of stroke, irrespective of other factors. We aimed to re-evaluate stroke risk factors in a contemporary cohort of AF patients.We analysed data of 15 400 AF patients presenting to an emergency department and who were enrolled in the global RE-LY AF registry, representing 47 countries from all inhabited continents. Follow-up occurred at 1 year after enrolment. A total of 1788 (11.6%) patients had RHD. These patients were younger (51.4±15.7 vs. 67.8±13.6 years), more likely to be female (66.2% vs. 44.7%) and had a lower mean CHA2DS2-VASc score (2.1±1.7 vs. 3.7±2.2) as compared to patients without RHD (all P<0.001). Significant mitral stenosis (average mean transmitral gradient 11.5±6.5 mmHg) was the predominant valve lesion in those with RHD (59.6%). Patients with RHD had a higher baseline rate of anticoagulation use (60.4% vs. 45.2%, P<0.001). Unadjusted stroke rates at 1 year were 2.8% and 4.1% for patients with and without RHD, respectively. The performance of the CHA2DS2-VASc score was modest in both groups [stroke at 1 year, c-statistics 0.69, 95% confidence interval (CI) 0.60-0.78 and 0.63, 95% CI 0.61-0.66, respectively]. In the overall cohort, advanced age, female sex, prior stroke, tobacco use, and non-use of anticoagulation were predictors for stroke (all P<0.05). Mitral stenosis was not associated with stroke risk (adjusted odds ratio 1.07, 95% CI 0.67-1.72, P=0.764).The performance of the CHA2DS2-VASc score was modest in AF patients both with and without RHD. In this cohort, moderate-to-severe mitral stenosis was not an independent risk factor for stroke.
Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease
Authors: Shervin Assassi, Ning Li, Elizabeth R. Volkmann, Maureen D. Mayes, Dennis Rünger, Jun Ying, Michael D. Roth, Monique Hinchcliff, Dinesh Khanna, Tracy Frech, Philip J. Clements, Daniel E. Furst, Jonathan Goldin, Elana J. Bernstein, Flavia V. Castelino, Robyn T. Domsic, Jessica K. Gordon, Faye N. Hant, Ami A. Shah, Victoria K. Shanmugam, Virginia D. Steen, Robert M. Elashoff, Donald P. Tashkin
Journal: Arthritis & Rheumatology (2020)

Response to immunosuppression is highly variable in systemic sclerosis (SSc)-related interstitial lung disease (ILD). This study was undertaken to determine whether a composite serum interferon (IFN)-inducible protein score exhibits predictive significance for the response to immunosuppression in SSc-ILD.
In vitro bone metastasis dwelling in a 3D bioengineered niche
Authors: Weijing Han, Rania El Botty, Elodie Montaudon, Laurent Malaquin, Frederic Deschaseaux, Nicolas Espagnolle, Elisabetta Marangoni, Paul Cottu, Gérard Zalcman, Maria Carla Parrini, Franck Assayag, Luc Sensebe, Pascal Silberzan, Anne Vincent-Salomon, Guillaume Dutertre, Sergio Roman-Roman, Stephanie Descroix, Jacques Camonis
Journal: Biomaterials (2020)
Large-Scale Proteomic and Phosphoproteomic Analyses of Maize Seedling Leaves During De-Etiolation
Authors: Zhi-Fang Gao, Zhuo Shen, Qing Chao, Zhen Yan, Xuan-Liang Ge, Tiancong Lu, Haiyan Zheng, Chun-Rong Qian, Bai-Chen Wang
Journal: Genomics Proteomics & Bioinformatics (2020)

Abstract De-etiolation consists of a series of developmental and physiological changes that a plant undergoes in response to light. During this process light, an important environmental signal, triggers the inhibition of mesocotyl elongation and the production of photosynthetically active chloroplasts, and etiolated leaves transition from the “sink” stage to the “source” stage. De-etiolation has been extensively studied in maize (Zea mays L.). However, little is known about how this transition is regulated. In this study, we described a quantitative proteomic and phosphoproteomic atlas of the de-etiolation process in maize. We identified 16,420 proteins in proteome, among which 14,168 proteins were quantified. In addition, 8746 phosphorylation sites within 3110 proteins were identified. From the combined proteomic and phosphoproteomic data, we identified a total of 17,436 proteins. Only 7.0% (998/14,168) of proteins significantly changed in abundance during de-etiolation. In contrast, 26.6% of phosphorylated proteins exhibited significant changes in phosphorylation level; these included proteins involved in gene expression and homeostatic pathways and rate-limiting enzymes involved in photosynthetic light and carbon reactions. Based on phosphoproteomic analysis, 34.0% (1057/3110) of phosphorylated proteins identified in this study contained more than 2 phosphorylation sites, and 37 proteins contained more than 16 phosphorylation sites, indicating that multi-phosphorylation is ubiquitous during the de-etiolation process. Our results suggest that plants might preferentially regulate the level of posttranslational modifications (PTMs) rather than protein abundance for adapting to changing environments. The study of PTMs could thus better reveal the regulation of de-etiolation.
Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes
Authors: Lauren G. Kanapka, R. Paul Wadwa, Marc D. Breton, Katrina J. Ruedy, Laya Ekhlaspour, Gregory P. Forlenza, Eda Cengiz, Melissa J. Schoelwer, Emily Jost, Lori Carria, Emma Emory, Liana J. Hsu, Stuart A. Weinzimer, Mark D. DeBoer, Bruce A. Buckingham, Mary Oliveri, Craig Kollman, Betsy B. Dokken, Daniel Cherñavvsky, Roy W. Beck
Journal: Diabetes Care (2020)

To further evaluate the safety and efficacy of the Control-IQ closed-loop control (CLC) system in children with type 1 diabetes.After a 16-week randomized clinical trial (RCT) comparing CLC with sensor-augmented pump (SAP) therapy in 101 children 6-13 years old with type 1 diabetes, 22 participants in the SAP group initiated use of the CLC system (referred to as SAP-CLC cohort), and 78 participants in the CLC group continued use of CLC (CLC-CLC cohort) for 12 weeks.In the SAP-CLC cohort, mean percentage of time in range 70-180 mg/dL (TIR) increased from 55 ± 13% using SAP during the RCT to 65 ± 10% using CLC (P < 0.001), with 36% of the cohort achieving TIR >70% plus time <54 mg/dL <1% compared with 14% when using SAP (P = 0.03). Substantial improvement in TIR was seen after the 1st day of CLC. Time <70 mg/dL decreased from 1.80% to 1.34% (P < 0.001). In the CLC-CLC cohort, mean TIR increased from 53 ± 17% prerandomization to 67 ± 10% during the RCT and remained reasonably stable at 66 ± 10% through the 12 weeks post-RCT. No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in either cohort.This further evaluation of the Control-IQ CLC system supports the findings of the preceding RCT that use of a closed-loop system can safely improve glycemic control in children 6-13 years old with type 1 diabetes from the 1st day of use and demonstrates that these improvements can be sustained through 28 weeks of use.
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial
Authors: Marco Ladetto, Sergio Cortelazzo, Simone Ferrero, Andrea Evangelista, Michael Mian, Rita Tavarozzi, Manuela Zanni, Federica Cavallo, Alice Di Rocco, Vittorio Stefoni, Chiara Pagani, Alessandro Re, Annalisa Chiappella, Monica Balzarotti, Vittorio R Zilioli, Maria Gomes da Silva, Luca Arcaini, Anna L Molinari, Filippo Ballerini, Andrés J M Ferreri, Benedetta Puccini, Fabio Benedetti, Piero M Stefani, Franco Narni, Ivana Casaroli, Caterina Stelitano, Giovannino Ciccone, Umberto Vitolo, Maurizio Martelli
Journal: The Lancet Haematology (2020)
Clinical Research Designs and Implantable Defibrillator Indications: Spend in the Beginning or Pay at the End⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily reflect the views of JACCor the American College of Cardiology.
Authors: Robert J. Myerburg, Agustin Castellanos
Journal: Journal of the American College of Cardiology (2006)
Chemical pancreatectomy treats chronic pancreatitis while preserving endocrine function in preclinical models
Authors: Mohamed Saleh, Kartikeya Sharma, Ranjeet Kalsi, Joseph Fusco, Anuradha Sehrawat, Jami L. Saloman, Ping Guo, Ting Zhang, Nada Mohamed, Yan Wang, Krishna Prasadan, George K. Gittes
Journal: Journal of Clinical Investigation (2020)

Chronic pancreatitis affects over 250,000 people in the US and millions worldwide. It is associated with chronic debilitating pain, pancreatic exocrine failure, and high risk of pancreatic cancer and usually progresses to diabetes. Treatment options are limited and ineffective. We developed a new potential therapy, wherein a pancreatic ductal infusion of 1%–2% acetic acid in mice and nonhuman primates resulted in a nonregenerative, near-complete ablation of the exocrine pancreas, with complete preservation of the islets. Pancreatic ductal infusion of acetic acid in a mouse model of chronic pancreatitis led to resolution of chronic inflammation and pancreatitis-associated pain. Furthermore, acetic acid–treated animals showed improved glucose tolerance and insulin secretion. The loss of exocrine tissue in this procedure would not typically require further management in patients with chronic pancreatitis because they usually have pancreatic exocrine failure requiring dietary enzyme supplements. Thus, this procedure, which should be readily translatable to humans through an endoscopic retrograde cholangiopancreatography (ERCP), may offer a potential innovative nonsurgical therapy for chronic pancreatitis that relieves pain and prevents the progression of pancreatic diabetes.
Consistency and Generalizability of Trials for Coronary Computed Tomography Angiography
Authors: David E. Newby, Philip D. Adamson, Leslee J. Shaw
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Low expression of HIV genes in podocytes accelerates the progression of diabetic kidney disease in mice
Authors: Jie Feng, Li Bao, Xuan Wang, Huilin Li, Yuqiang Chen, Wenzhen Xiao, Zhengzhe Li, Liyi Xie, Wanhong Lu, Hongli Jiang, Kyung Lee, John Cijiang He
Journal: Kidney International (2020)
Pandemic trials: evidence-based medicine on steroids
Authors: James D. Chalmers
Journal: European Respiratory Journal (2020)

<b>Small trials have been largely overlooked in the early part of the COVID-19 pandemic in favour of "mega-trials". As new therapies are urgently needed, phase 2 "proof of concept" studies are crucial as we move into a new phase of pandemic research.</b>https://bit.ly/3o0K9kl
Poly(α-l-lysine)-based nanomaterials for versatile biomedical applications: Current advances and perspectives
Authors: Maochao Zheng, Miao Pan, Wancong Zhang, Huanchang Lin, Shenlang Wu, Chao Lu, Shijie Tang, Daojun Liu, Jianfeng Cai
Journal: Bioactive Materials (2020)

Poly(α-l-lysine) (PLL) is a class of water-soluble, cationic biopolymer composed of α-l-lysine structural units. The previous decade witnessed tremendous progress in the synthesis and biomedical applications of PLL and its composites. PLL-based polymers and copolymers, till date, have been extensively explored in the contexts such as antibacterial agents, gene/drug/protein delivery systems, bio-sensing, bio-imaging, and tissue engineering. This review aims to summarize the recent advances in PLL-based nanomaterials in these biomedical fields over the last decade. The review first describes the synthesis of PLL and its derivatives, followed by the main text of their recent biomedical applications and translational studies. Finally, the challenges and perspectives of PLL-based nanomaterials in biomedical fields are addressed.
Electronic Communication and Health Care: US doctors want to be paid for email communication with patients
Authors: Scott Gottlieb
Journal: BMJ (2004)

Email is becoming a more common tool of clinical practice, enabling doctors to communicate with patients between office visits, improve diagnosis and compliance with medical treatments, and facilitate medical record keeping, says a report in the New England Journal of Medicine ( 2004;350: 1705-7) [PubMed].

“Judging from our early experience in a practice that offers secure electronic communication, e-mail gives doctors and patients more time to think,” wrote Dr Tom Delbanco and Dr Daniel Sands of the Beth Israel Deaconess Medical Center in Boston and Harvard Medical School. “Doctors and patients move closer together, and trust grows strikingly. Interchange becomes more personal, and office visits seem more efficient and less emotionally charged.”

Although many doctors continue to use conventional email, some hospitals have set up messaging systems on secure websites to protect patients' privacy. At the Beth Israel Deaconess Medical Center, 18 000 patients routinely log on to a protected website called PatientSite to request refills, write to doctors, or scan personal medical records.

“And with time offline to reflect and learn, patients appear to be better able to grasp information that is central to their care. Indeed, one of our patients told us, `Exchanges by e-mail are the next best thing to a house call,'” the authors wrote.

About a quarter of practising doctors, surveys show, have communicated with patients through email. But many doctors feel that it means working free of charge, and some have begun charging for email consultations.

In some cases, patients pay a flat rate from $100 (£56; €84) to several hundred dollars a year for such services, said Dr Sands, an assistant professor of medicine at the Harvard Medical School.

Urged on by the American Medical Association and the American College of Physicians, insurers and health plans are exploring ways of paying doctors for using email, whether by the message or episode of illness.
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy
Authors: Astha Thakkar, Kith Pradhan, Shawn Jindal, Zhu Cui, Bradley Rockwell, Akash Pradip Shah, Stuart Packer, R. Alejandro Sica, Joseph Sparano, D. Yitzhak Goldstein, Amit Verma, Sanjay Goel, Balazs Halmos
Journal: Nature Cancer (2021)
A decentralised point-of-care testing model to address inequities in the COVID-19 response
Authors: Belinda Hengel, Louise Causer, Susan Matthews, Kirsty Smith, Kelly Andrewartha, Steven Badman, Brooke Spaeth, Annie Tangey, Phillip Cunningham, Amit Saha, Emily Phillips, James Ward, Caroline Watts, Jonathan King, Tanya Applegate, Mark Shephard, Rebecca Guy
Journal: The Lancet Infectious Diseases (2020)
Use of Tablo Hemodialysis Systems to Extend Dialytic Capabilities for the COVID-19-Associated Surge of AKI
Authors: David S. Goldfarb, Jessica M. Yan, Matthew A. Gross, Clay A. Block
Journal: Journal of the American Society of Nephrology (2020)

Background: The COVID-19 pandemic was associated with a greater incidence of AKI than expected  At the NY Harbor VA we faced an overwhelming number of AKI patients who were critically ill with multi-organ failure  We needed to invoke new mechanisms of providing kidney replacement therapy (KRT)  Methods: We obtained 3 Tablo systems in late March, 2019  The machines have selfcontained reverse osmosis capabilities and so do not require other equipment to operate  They can make dialysate from concentrate and tap water and so do not require special plumbing adaptation  Their self-contained step-by-step procedures are relatively simple to follow and allow rapid training of previously unskilled personnel  Tablo generates 300 ml dialysate per minute, and blood flow was increased to up to 400 ml/min as tolerated  Results: Training was completed by 2 nephrologists and 2 RNs without previous dialysis experience  We used the Tablo Hemodialysis System to provide KRT to critically ill patients  In the first week we demonstrated that water cultures and endotoxin testing were negative, and that AAMI water tests were acceptable  We used the machines to provide KRT for ICU patients with double-lumen dialysis catheters  In addition we used the machines on hospital wards where KRT had not been provided before because of a lack of the plumbing needs of conventional HD machines  We provided multiple treatments 3-6 times per week for 15 AKI patients, mean age 65 years  The mean of the best urea reduction ratio achieved in the first 1-4 treatments, if available, was 41% (often limited by hypotension and fulfillment of ultrafiltration, UF, needs)  Most treatments were successful and were slowed for hypotension or tachycardia  Some were aborted because of water pressure alarms if sediment filters needed replacement, or lines clotted due to hypercoagulability associated with COVID-19  Personnel availability dictated that most treatments were 3-4 hours (and up to 8h), and generally achieved UF goals  Later HD nurses cannulated arteriovenous fistulas in ESKD patients and left treatment to non-HD nurses to complete  Conclusions: By incorporating a user-friendly platform and an accelerated training program including nephrologists and RNs without previous dialysis experience, we were able to nearly double our capacity to deliver KRT during the surge